The subscription period in Alligator Bioscience’s rights issue commences today
Today is the first day of the subscription period in Alligator Bioscience AB (publ)’s (“Alligator” or the “Company”) rights issue of shares ...
Alligator Bioscience publishes prospectus in connection with forthcoming rights issue
The Board of Directors of Alligator Bioscience AB (publ) ("Alligator" or the "Company") has, in connection with the rights i ...
Alligator Bioscience recruits new Chief Medical Officer
Lund, Sweden, December 29, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company has appointed Dr Christina ...
Alligator Bioscience submits CTA for the mitazalimab Phase II study OPTIMIZE-1
Lund, Sweden, December 28, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it has submitted a CTA (Clinical Trial ...
Alligator carries out a fully guaranteed rights issue of approximately SEK 86m
The Board of Directors of Alligator Bioscience AB (publ) ("Alligator" or the "Company") has today, based on the authorizatio ...
Alligator Bioscience launches ALLIGATOR-FAB™ – a novel human antibody library
Lund, Sweden, December 10, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the completion of a novel proprietary human ...
Approved IND for Alligator Bioscience’s CD40-targeting antibody mitazalimab
Lund, Sweden, December 4, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an approved IND (Investigational new Drug) f ...
Nomination Committee appointed in respect of AGM 2021 in Alligator Bioscience AB
Lund, Sweden, November 20, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the Nomination Committee in preparatio ...
Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development
Lund, Sweden and Seattle, WA – November 16, 2020 – Alligator Bioscience (“Alligator”) (Nasdaq Stockholm: ATORX), a biotechnology company dev ...